TrialAIDS (London, England)2026

Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.

Andrew Carr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.